Cassava Sciences, Inc. (SAVA)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 39.54 |
| Open | 37.94 |
| Bid | 39.26 x 900 |
| Ask | 39.99 x 3100 |
| Day's range | 37.65 - 41.08 |
| 52-week range | 14.48 - 146.16 |
| Volume | |
| Avg. volume | 4,726,138 |
| Market cap | 1.601B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | N/A |
- Zacks
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
- Motley Fool
Where Will Cassava Sciences Be in 1 Year?
First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.
- Motley Fool
3 Healthcare Stocks That Could Rocket Higher in 2022
A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.
© 2022 Yahoo. All rights reserved.
